Get the Stockscreener App
12.85
1.73%
0.1504
Q 32 Bio Inc stock is traded at $12.85, with a volume of 278.95K.
It is up +1.73% in the last 24 hours and up +122.38% over the past month.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
See More
Previous Close:
$12.70
Open:
$12.7
24h Volume:
278.95K
Relative Volume:
0.39
Market Cap:
$217.55M
Revenue:
$53.74M
Net Income/Loss:
$33.24M
P/E Ratio:
4.8252
EPS:
2.6632
Net Cash Flow:
$-27.40M
1W Performance:
-1.45%
1M Performance:
+122.38%
6M Performance:
+336.49%
1Y Performance:
+660.00%
1-Day Range:
$12.63
$13.71
1-Week Range:
$11.08
$13.99
52-Week Range:
$1.345
$14.85
Q 32 Bio Inc Stock (QTTB) Company Profile
Name
Q 32 Bio Inc
Sector
Industry
Phone
781-999-0232
Address
830 WINTER STREET, WALTHAM
Compare QTTB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QTTB
Q 32 Bio Inc
|
12.83 | 215.35M | 53.74M | 33.24M | -27.40M | 2.6632 |
VRTX
Vertex Pharmaceuticals Inc
|
445.21 | 112.95B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
613.72 | 64.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.71 | 55.90B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
283.01 | 38.64B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.44 | 31.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Q 32 Bio Inc Stock (QTTB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | H.C. Wainwright | Buy |
| Feb-11-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-11-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-11-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-11-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | Raymond James | Strong Buy |
| Sep-11-24 | Initiated | Wells Fargo | Overweight |
| Jun-17-24 | Initiated | Guggenheim | Buy |
| May-21-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-22-22 | Reiterated | BTIG Research | Neutral |
| Feb-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-22-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-02-21 | Initiated | Stifel | Hold |
| Dec-14-20 | Resumed | H.C. Wainwright | Buy |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-16-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-24-20 | Initiated | Chardan Capital Markets | Buy |
| Nov-01-19 | Initiated | Oppenheimer | Perform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
View All
Q 32 Bio Inc Stock (QTTB) Latest News
Atlas Venture fund discloses 625,000 Q32 Bio (QTTB) common shares held - Stock Titan
Q32 Bio Raises $55 Million in Private Placement - Global Legal Chronicle
ORBIMED ADVISORS LLC's Strategic Acquisition in Q32 Bio Inc - GuruFocus
QTTB News | Q32 BIO INC (NASDAQ:QTTB) - ChartMill
Biotechnology Value Fund (QTTB) group reports 2.37M-share position, 150k warrants - Stock Titan
RA Capital affiliates disclose 2.33M-share stake in Q32 Bio (QTTB) - Stock Titan
Q32 Bio Inc. Stock (QTTB) Opinions on Massive Price Surge - Moomoo
Monday’s insider activity: Q32 Bio and Outlook see major buys By Investing.com - Investing.com South Africa
Monday’s insider activity: Q32 Bio and Outlook see major buys - Investing.com
OrbiMed entities acquire $15m in Q32 Bio stock - Investing.com
OrbiMed-backed funds add 1.88M Q32 Bio (QTTB) shares in private placement - Stock Titan
Q32 Bio director Xu Diyong buys $15m common stock - Investing.com
OrbiMed boosts Q32 Bio (QTTB) ownership to 17.4% after May 2026 PIPE - Stock Titan
Q32 Bio Company Profile & Introduction - Moomoo
Q32 Bio Inc. Common Stock (QTTB) Stock Price Today & Analysis - Gotrade
Why Is Q32 Bio Stock Gaining Friday? - Benzinga
QTTB Stock Chart | Q32 BIO INC (NASDAQ:QTTB) - ChartMill
Atlas Venture funds (QTTB) join Q32 Bio $5M PIPE deal - Stock Titan
Q32 Bio, Inc. Hits New 52-Week High of $13.15 - MarketsMojo
Q32 Bio: "Buy" On Bempikibart Advancement And Mid-2026 Data Catalysts (NASDAQ:QTTB) - Seeking Alpha
Q32 Bio (QTTB) Is Up 126.6% After US$55M Private Placement With Top Healthcare FundsHas The Bull Case Changed? - simplywall.st
Q32 Bio announces $55M private placement - MSN
Q32 Bio (NASDAQ: QTTB) prices $55M stock and pre-funded warrant sale - Stock Titan
Q32 Bio Inc. (QTTB) Stock: Surges After $55 Million Private Placement Led by Top Biotech Investors - parameter.io
Q32 Bio Inc. (QTTB) Secures $55M in Private Placement of Common Stock - GuruFocus
Q32 Bio Secures $55 Million Private Placement to Advance Alopecia Areata Pipeline (QTTB) - Yahoo Finance
Q32 Bio Inc. announced that it expects to receive $53.8 million in funding from Atlas Venture Advisors, Inc., OrbiMed Advisors LLC, BVF Partners L.P., RA Capital Management, L.P. - marketscreener.com
Q32 Bio announces $55 million private placement financing - marketscreener.com
Q32 Bio Announces $55 Million Private Placement Financing - PR Newswire
QTTB - Finviz
Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 145.69%: Read This Before Placing a Bet - Yahoo Finance
Q32 Bio Q1 2026 Earnings: Narrowed Loss Exceeds Expectations, Stock RisesAdjusted Earnings Analysis - The Legal Advocate
This Q32 Bio analyst begins coverage on a bullish note; here are top 3 initiations for Friday - MSN
This Q32 Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday - Benzinga
Mizuho initiates Q32 Bio stock coverage with Outperform rating - Investing.com UK
QTTB | Q32 Bio Inc. Common Analyst Forecasts - Quiver Quantitative
Mizuho initiates Q32 Bio stock coverage with Outperform rating By Investing.com - Investing.com Australia
Q32 BIO INC. (QTTB) - MSN
Q32 Bio gears up to report Q1 earnings: What's in the cards? - MSN
Point72 reports 958,768-share (5.7%) stake in Q32 Bio (QTTB) - Stock Titan
Sirenia and Alex Silverstein report 9.9% stake in Q32 Bio (QTTB) - Stock Titan
Q32 Bio (QTTB) Stock Price, News & Analysis - MarketBeat
Number of shareholders of Q32 Bio Inc. – NASDAQ:QTTB - TradingView
Number of shareholders of Q32 Bio Inc. – BOATS:QTTB - TradingView
The organic vs inorganic growth story at Q32 Bio (QTTB) | Q4 2025: EPS Beats ForecastsReal-time Trade Ideas - newser.com
QTTB SEC FilingsQ32 BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
QTTB Q32 Bio posts massive EPS beat, yet shares dip despite blowout quarter.Working Capital - newser.com
How Q32 Bio (QTTB) guidance shapes future expectations | Q4 2025: Profit SurprisesRevenue Inflection Point - The Legal Advocate
Why Q32 Bio (QTTB) might be the portfolio Builder you need (+6.42%) 2026-05-06Fundamentals - newser.com
Q 32 Bio Inc Stock (QTTB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Q 32 Bio Inc Stock (QTTB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
May 28 '26 |
Buy |
8.00 |
1,875,000 |
15,000,000 |
3,502,987 |
| Kalowski Lee | CFO and President |
Feb 25 '26 |
Sale |
4.51 |
3,995 |
18,035 |
35,943 |
| Morrison Jodie Pope | CEO |
Feb 25 '26 |
Sale |
4.51 |
9,896 |
44,675 |
89,104 |
| Violette Shelia M. | Chief Scientific Officer |
Feb 25 '26 |
Sale |
4.51 |
2,815 |
12,708 |
55,569 |
| Morrison Jodie Pope | CEO |
Dec 02 '25 |
Sale |
3.46 |
22,506 |
77,871 |
99,000 |
| Kalowski Lee | CFO and President |
Dec 02 '25 |
Sale |
3.46 |
9,072 |
31,395 |
39,938 |
0.23%
1.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):